Reports and Briefs

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

5EU: Pricing, Reimbursement and Regulatory Update

Datamonitor’s report 5EU: Pricing, Reimbursement, and Regulatory Update provides an overview of developments regarding healthcare reforms, drug regulation, and drug pricing and reimbursement in France, Germany, Italy, Spain, and the UK.

Published By Datamonitor
28 Oct 2011 $1520
Buy
Report
Report

Abbott Laboratories: Company Analysis

Analysis of Abbott's corporate strategy, marketed portfolio, pipeline potential and financial position in 2011 and to 2017

Published By Datamonitor
08 Aug 2012 $2800
Buy
Report
Report

Accelerating Lead Generation

The number of approvals for new drugs has fallen steadilyin recent years, despite increasing R&D expenditure. Improvements in lead generation essential for companies aiming to avoid expensive compound failures in the later stages of development.

Published By Business Insights
01 Jun 2009 $3835
Buy
Report
Report

Accelerating Lead Generation: Emerging technologies and strategies

'Accelerating Lead Generation: Emerging technologies and strategies' provides an in-depth examination of state-of-the-art technologies for lead generation. This report assesses the potential of new and emerging technologies for improving the quality of drug candidates entering clinical research, and reviews the benefits associated with different approaches to lead generation, including high throughput screening, fragment based drug discovery and virtual screening.

Published By Business Insights
01 Jun 2009 $3835
Buy
Report
Report

Acorda Therapeutics: PharmaVitae Report

Analysis of Acorda Therapeutics' corporate history, corporate relationships, prospects to the end of the forecast period, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.

Published By Datamonitor
11 May 2012 $2800
Buy
Report
Report

Actelion Ltd: PharmaVitae Report

Analysis of Actelion's corporate strategy, marketed portfolio, pipeline potential and financial position in 2010 and to 2016

Published By Datamonitor
20 Oct 2011 $2800
Buy
Premium Report
Premium Report

Actinic Keratosis Therapy Area Pipeline Report - Q3 2010

Life Science Analytics', Actinic Keratosis Therapy Area Pipeline Report contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of acne drugs by company and by stage as well as a summary of the latest news and developments in this area. This report is updated every quarter.

Published By Life Science Analytics
13 Sep 2010 $1495
Buy
Premium Report
Premium Report

Advances in Alzheimer’s Disease Drug Discovery

It is estimated that 115 million people globally will have Alzheimer's disease by 2050. In the US alone, a cost of $1,000bn is predicted. Disease-modifying therapies that delay the onset of AD or slow its progression are a major unmet medical need.

Published By Scrip Insights
26 May 2011 $3835
Buy
Report
Report

Advances in Alzheimer’s Disease Drug Discovery

It is estimated that 115 million people globally will have Alzheimer's disease by 2050. In the US alone, a cost of $1,000bn is predicted. Disease-modifying therapies that delay the onset of AD or slow its progression are a major unmet medical need.

Published By Business Insights
26 May 2011 $3835
Buy
Premium Report
Premium Report

Advances in Delivery to the Central Nervous System

CNS drugs are associated with longer development times and higher attrition rates than drugs for other therapy areas. Advances in delivery technologies are essential if the pursuit of novel treatments is to remain commercially viable.

Published By Scrip Insights
31 Aug 2012 $2875
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.